Phase 2 Oesophageal Cancer Trial, Recruiting NCT07519486 Sponsor: Sichuan University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT07519486
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by laboratory testing
  • People aged between 18 and 80 years, of any gender
  • People whose general physical condition is rated as reasonably functional (on a standard medical scale), and who have not lost more than 10% of their body weight in the past 6 months
  • People whose cancer has been assessed as locally advanced and not removable by surgery, based on established medical guidelines
  • People whose treatment plan includes surgery after an initial course of therapy to try to shrink the tumour, and who have no medical reasons preventing surgery
  • People who have not previously received any treatment for this cancer, including radiation, chemotherapy, or surgery
  • People who have at least one measurable tumour area based on standard imaging criteria
  • People whose expected survival is at least 3 months
  • People who are able to swallow and take oral medications
  • People whose blood counts, organ function, and other laboratory results meet the levels required by the trial
  • Women who could become pregnant, and men, who agree to use effective contraception throughout the trial and for 6 months after it ends
  • People who are willing to participate voluntarily and have signed a consent form

Who may not be able to join:

  • People who have a fistula (an abnormal connection) between the oesophagus and the airway or chest cavity, or whose tumour is growing into major blood vessels in a way that could cause life-threatening bleeding
  • People who have had another type of cancer in the past 5 years
  • People who have used medications that suppress the immune system, or steroid medications above a certain dose, within 2 weeks before starting the trial
  • People who have an active autoimmune disease, or a history of autoimmune disease that has required ongoing medical treatment
  • People with a known history of immune system deficiency, including HIV infection, or those who have had an organ transplant or bone marrow transplant
  • People with other serious uncontrolled health conditions, such as uncontrolled high blood pressure, unstable heart conditions, a recent heart attack, or severe infections
  • People with active tuberculosis (TB), or a history of TB that was not fully treated
  • People with active Hepatitis B or Hepatitis C infection
  • People who are completely unable to take any nutrition or medication by mouth due to severe narrowing of the oesophagus
  • People who have, or have had, significant scarring or inflammation in the lungs (interstitial lung disease)
  • People with uncontrolled fluid build-up around the lungs, heart, or abdomen that requires repeated draining
  • People with significant bowel problems causing severe diarrhoea
  • People who are pregnant or currently breastfeeding
  • People who have taken part in another clinical trial within the 30 days before enrolling

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhenyu Ding, PhD, West China Hospital

Phone: +86-189-8060-1957

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sichuan University
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 September 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological Complete Response (pCR) Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov